ProPublica Investigates Generic Drug Safety—and Valisure’s Role
ProPublica has launched a major investigative series exposing deep flaws in the generic drug supply chain and the regulatory systems meant to protect patients. These findings directly align with Valisure’s mission to bring greater transparency, accountability, and independent testing to the pharmaceutical industry.
The series opens with Threat in Your Medicine Cabinet: The FDA’s Gamble on America’s Drugs, which details how the FDA allowed drugs from overseas factories to enter the U.S. market with little to no inspection—relying instead on self-reported data from manufacturers, many of which have a history of quality issues.
The follow-up story, His Kidney Failed. He’ll Never Know if a Transplant Drug From a Banned Factory Was to Blame, takes a closer look at tacrolimus, a critical transplant drug. Valisure’s testing uncovered key quality issues with this medication, which was manufactured at a facility later banned from shipping to the U.S.
These investigations underscore the urgent need for independent oversight and reinforce why Valisure continues to push for stronger safeguards in our drug supply.
We’ll continue to share future articles in this important series as they’re released.
